Kemal is a toxicologist with 20+ years’ experience in the biopharmaceutical sector in both large pharma and small biotech organisations (AstraZeneca, Medimmune, OSI Pharmaceuticals, Karus Therapeutics).  He has supported small molecule and biologics projects from early discovery through clinical development and licensing, authored non-clinical safety sections of submission documents, and supported regulatory interactions.  In addition, Kemal has considerable experience of due diligence and in/out-licensing activities.

Kemal has a first degree in Cellular and Molecular Pathology, a PhD in Carcinogenesis, and is a Fellow of the Royal Society of Biology.